CEO Interview: Learn How BioVie is Pioneering New Approaches in Neurodegenerative Disease Treatments
Oct. 7, 2024
BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation that leads to neuroinflammation, and insulin resistance believed to be drivers of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis.
Visit www.redchip.com/stocks/BIVI to learn more.
